Theranostic barcoded nanoparticles for personalized cancer medicine
Menée à l'aide d'un modèle murin de cancer du sein triplement négatif, cette étude met en évidence, dans le cadre d'une médecine personnalisée, l'intérêt de nanoparticules liposomiques contenant un médicament et une séquence d'ADN synthétique, servant de code-barres génétique, pour traiter une tumeur et évaluer parallèlement l'efficacité du traitement
Personalized medicine promises to revolutionize cancer therapy by matching the most effective treatment to the individual patient. Using a nanoparticle-based system, we predict the therapeutic potency of anticancer medicines in a personalized manner. We carry out the diagnostic stage through a multidrug screen performed inside the tumour, extracting drug activity information with single cell sensitivity. By using 100 nm liposomes, loaded with various cancer drugs and corresponding synthetic DNA barcodes, we find a correlation between the cell viability and the drug it was exposed to, according to the matching barcodes. Based on this screen, we devise a treatment protocol for mice bearing triple-negative breast-cancer tumours, and its results confirm the diagnostic prediction. We show that the use of nanotechnology in cancer care is effective for generating personalized treatment protocols.